A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

详细信息	查看全文 | 推荐本文 |

• 作者：Jing-Hui Tian^a ; ³ ; Steven R. Fuhrmann^a ; ¹ ; Stefanie Kluepfel-Stahl^a ; ² ; Robert J. Carman^b ; Larry Ellingsworth^a ; David C. Flyer^a ; ³ ; ^{dcflyer51@gmail.com} ; ^{dflyer@novavax.com}
• 关键词：CDAD ; Clostridium difficile associated disease ; RBD ; receptor binding domains ; C-TAB ; carboxy-terminal toxin A and B ; C-TAB.G5 ; C-TAB generation 5 ; PRAS ; pre-reduced anaerobically sterilized ; MLD100 ; minimum 100%lethal dose ; ED50 ; 50%effective dose
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：13 June, 2012
• 卷：30
• 期：28
• 页码：4249-4258
• 文件大小：811 K

摘要

Antibodies targeting the Clostridium difficile toxin A and toxin B confer protective immunity to C. difficile associated disease in animal models and provided protection against recurrent C. difficile disease in human subjects. These antibodies are directed against the receptor binding domains (RBD) located in the carboxy-terminal portion of both toxins and inhibit binding of the toxins to their receptors. We have constructed a recombinant fusion protein containing portions of the RBD from both toxin A and toxin B and expressed it in Escherichia coli. The fusion protein induced high levels of serum antibodies to both toxins A and B capable of neutralizing toxin activity both in vitro and in vivo. In a hamster C. difficile infection model, immunization with the fusion protein reduced disease severity and conferred significant protection against a lethal dose of C. difficile spores. Our studies demonstrate the potential of the fusion protein as a vaccine that could provide protection from C. difficile disease in humans.